Azenta突发CEO离任并确认Q4约300万美元一次性费用，股价盘中已跌近12%

Shares of Azenta (AZTA), a life sciences sample management and genomics services company, tumbled almost 12% on Monday after the company announced a surprise leadership change. The firm revealed that John Marotta is resigning as President, CEO, and director, with board member Martin Madaus stepping in as interim chief executive.
Along with the leadership transition, Azenta disclosed a one-time consulting expense of roughly $3 million that will weigh on fourth-quarter fiscal 2026 adjusted EBITDA, even as the company reaffirmed its previously issued Q4 revenue guidance.{"type": "symbol-chart", "props": {"ticker": "AZTA"}, "data": [{"symbol": {"id": 1999, "slug": "azta", "name": "AZTA", "company": "Azenta, Inc.", "company_name": "Azenta, Inc.", "equity_type": "stocks", "fund_type_id": 0, "followers_count": 6211, "div_yield_type": "historic", "index_group": null, "is_bdc": false, "is_reit": false, "is_currency": false, "is_crypto": false, "is_mutual_funds": false, "is_etf": false, "is_cef": false, "is_index": false, "is_bond": false, "is_commodity": false}, "prices": {"id": 1999, "last": 33.02, "change": -4.379999999999995, "percent_change": -11.7112, "last_time": "2026-08-24T15:58:45.000-04:00", "high": 34.22, "low": 31.87, "open": 33.62, "prev_close": 37.4, "volume": 1634827.305811}, "ratings": {"quant_rating": 3.179695607056382, "sell_side_rating": 3.83333, "authors_rating": 3.0}, "key_data": {"last_close_price_earnings_ratio": null, "div_rate_fwd": null, "div_rate_ttm": null, "div_yield_fwd": null, "dividend_yield": null, "short_interest_shares_outstanding": 12.18752762741149, "marketcap": 1638433900.0, "impliedmarketcap": null, "estimate_eps": 0.37, "diluted_eps_excl_extra_itmes": -2.459756, "estimate_ffo": null, "ffo_per_share_diluted": null, "pe_ratio_fwd": 101.081081081081}}]}
The table below showcases the stock's daily activity over the past few days:
{"type": "table", "props": {"data": [{"date": "Aug 21, 2026", "return": "+2.44%"}, {"date": "Aug 20, 2026", "return": "+2.50%"}, {"date": "Aug 19, 2026", "return": "+8.00%"}, {"date": "Aug 18, 2026", "return": "-1.79%"}, {"date": "Aug 17, 2026", "return": "+0.60%"}, {"date": "Aug 14, 2026", "return": "-1.56%"}, {"date": "Aug 13, 2026", "return": "+1.13%"}, {"date": "Aug 12, 2026", "return": "+0.42%"}, {"date": "Aug 11, 2026", "return": "+0.18%"}, {"date": "Aug 10, 2026", "return": "+4.03%"}], "columns": [{"header": "Date", "accessor": "date", "align": "left"}, {"header": "Daily Return", "accessor": "return", "align": "right", "component": {"type": "signed-value"}}], "title": "AZTA Daily Returns"}}
August 5, 2026: Azenta reported Q3 fiscal 2026 results, with non-GAAP EPS of $0.16, beating consensus estimates by $0.06, on revenue of $161.18 million, up nearly 12% year over year and ahead of estimates by $11.95 million. The company raised full-year fiscal 2026 revenue guidance to $613 million-$618 million and adjusted EBITDA guidance to $59 million-$62 million. Read more
MarketGyrations (August 14) assigned a neutral rating to AZTA, noting the stock had rallied strongly off a multi-year low reached in May 2026 but cautioning that the advance could reverse. The analysis highlighted that Azenta's fiscal 2026 guidance falls short of the company's own long-term financial model, which targets 6-8% annual revenue growth and a 26.94% adjusted EBITDA compound annual growth rate through fiscal 2028. Read more